Chronic thrombotic microangiopathy associated with antineoplastic therapy with minimal hematologic effects

Mayo Clinic Proceedings

Volumn 77, Issue 4, 2002, Pages 323-328

  Raife, Thomas J ^a   Lager, Donna J ^b  

^a UNIVERSITY OF IOWA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; MITOMYCIN; PREDNISONE; PROCARBAZINE; VIDARABINE; VINCRISTINE;

ADULT; ARTICLE; CHILD; ELECTRON MICROSCOPY; FEMALE; HEMATOLOGIC DISEASE; HEMOLYSIS; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; MEDICAL RECORD; PLASMAPHERESIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; UREMIA;

EID: 0036197851     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/77.4.323     Document Type: Article

References (37)

1. A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma
2. Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy
3. Plasma exchange and vincristine in the treatment of hemolytic uremic syndrome/thrombotic thrombocytopenic purpura associated with bone marrow transplantation
4. Intravascular hemolysis and renal insufficiency after bone marrow transplantation
5. Haemolytic uraemic syndrome after bone marrow transplantation: An adverse effect of total body irradiation?
6. Thrombotic microangiopathy in the cancer patient including those induced by chemotherapeutic agents
7. Miscellaneous secondary thrombotic microangiopathy
8. Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies
9. Cancer-associated hemolytic-uremic syndrome: Analysis of 85 cases from a national registry
10. Hemolytic uremic syndrome following bone marrow transplantation: A case report and review of the literature
11. A case of thrombotic thrombocytopenic purpura following allogeneic bone marrow transplantation
12. Clinical course of late-onset bone marrow transplant nephropathy
13. Thrombotic microangiopathy following bone marrow transplantation
14. Mesangiolysis: An important glomerular lesion in thrombotic microangiopathy
15. Thrombotic microangiopathy including hemolytic uremic syndrome, thrombotic thrombocytopenic purpura and postpartum renal failure
16. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura
17. Thrombotic microangiopathies in the 1980s: Clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic
18. Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation
19. Thrombotic thrombocytopenic purpura: A simpler diagnosis at last?
20. Von Willebrand factor in thrombotic thrombo-cytopenic purpura
21. Changes in the natural anticoagulants following bone marrow transplantation
22. High frequency of antithrombin 3 and protein C deficiency following autologous bone marrow transplantation for lymphoma
23. Protein C deficiency following hematopoietic stem cell transplantation (HSCT): Optimization of intravenous (IV) vitamin K (VK) dose
24. Cerebral infarction associated with protein C deficiency following allogeneic bone marrow transplantation
25. Protein C (PC) deficiency during marrow transplantation: A frequent occurrence associated with a decrease in PC antigen and production of a dysfunctional PC molecule
26. Renal vascular lesions after chemotherapy with vinblastine, bleomycin, and cisplatin
27. Delayed renal failure with extensive mesangiolysis following bone marrow transplantation
28. Treatment of radiation nephropathy with ACE inhibitors
29. Treatment of radiation nephropathy with captopril
30. Radiation nephropathy: A review
31. Noncontinuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy
32. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function
33. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: A potential link between the renin-angiotensin system and thrombosis
34. Angiotensin II induces secretion of plasminogen activator inhibitor 1 and a tissue metalloprotease inhibitor-related protein from rat brain astrocytes
35. Effects of captopril therapy on endogenous fibrinolysis in men with recent, uncomplicated myocardial infarction
36. Improvement in endothelial function by angiotensin-converting enzyme inhibition in insulin-dependent diabetes mellitus
37. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency